Start-Up Previews, November 2014
Executive Summary
The emerging life sciences companies profiled in the November issue of Start-Up: ImmuneXcite, Inivata, Lumoptik, NanoSomiX, and Scholar Rock.
You may also be interested in...
Lumoptik Inc.
VEGF inhibitors have revolutionized the treatment of age-related macular degeneration, but there’s no getting around the need for lifelong, monthly injections straight into the eye. Lumoptik Inc. has developed a precision navigation system that may allow for more effective, prolonged drug delivery, resulting in less frequent injections over the same time period.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.